The approval is supported by data from the phase 3 STOP 301 study, which evaluated the safety and tolerability of Trudhesa in 354 adults with migraine. The Food and Drug Administration has approved ...

The US Food and Drug Administration (FDA) has approved an intranasal formulation of dihydroergotamine mesylate (DHE) for the acute treatment of migraine with or without aura in adults. Trudhesa ...

The FDA has accepted a filing for approval of Impel NeuroPharma’s INP104 for the acute treatment of migraine. If approved, INP104 will become the first commercial product based on Impel’s technology ...

Nasal congestion occurs when blood vessels and mucous membranes in the sinuses and nasal passageways swell. While mild congestion often clears on its own, a range of treatments and home remedies can ...

Migraines are difficult to navigate, with patients often mapping their own routes to try to avoid the debilitating episodes and to deal with them when they arise. Impel NeuroPharma’s new campaign ...

This condition can impair breathing, smell, and overall quality of life. Proper treatment can help reduce inflammation in your sinuses and nasal passages, as well as decrease polyp size, to help ease ...

Nasal cancer, a rare but increasing cancer, affects men more than women. It originates in the nasal cavity or sinuses. Risk factors include occupational exposure to dusts and chemicals, smoking, and ...

Small, persistent changes in the nose or face are easy to ignore, but in some cases they are the earliest signs of a much more serious disease.

Nasal valve collapse causes the airways in the nose to narrow. This can result in breathing difficulties and significantly affect a person’s quality of life. Surgery is often necessary, but ...

Trudhesa uses proprietary technology to deliver a lower dose (0.725mg per spray) of dihydroergotamine mesylate to the upper nasal space. Trudhesa (dihydroergotamine mesylate) nasal spray is now ...